重组PTD-maxadilan的制备与鉴定

Preparation and identification of recombinant PTD-maxadilan

摘要:

为了构建能够有效进入血脑屏障的新型融合蛋白PTD-maxadilan(PTD-MAX), 设计编码融合蛋白PTD-MAX基因, 克隆到表达载体pKYB, 构建重组表达载体pKYB-PTD-MAX, 转化大肠杆菌ER2566中。采用IPTG诱导由PTD-MAX、内含肽和几丁质组成的融合蛋白的表达。利用IMPACT(Intein Mediated Purification with an Affinity Chitin-binding Tag)介导的纯化系统制备目的融合蛋白PTD-MAX。所得的目的蛋白经激光飞行质谱测定分子量, 结果与理论值相符。动物实验结果表明融合蛋白PTD-MAX能够有效穿越血脑屏障, 重组PTD-MAX具有比天然maxadilan更显著(P<0.05)的抑制小鼠摄食的作用。融合蛋白PTD-MAX的构建和制备为其生物学功能的深入开发奠定了基础。

Abstract:

In order to construct a novel fusion protein PTD-maxadilan (PTD-MAX) that can enter the blood-brain barrier (BBB) efficiently, a new gene encoding PTD-MAX was synthesized and cloned into the expression vector pKYB. The recombinant vector pKYB-PTD-MAX was transformed into Escherichia coli ER2566. The expression of fusion protein consisting of PTD-MAX, intein and chitin binding domain was induced by IPTG and the target PTD-MAX protein was purified using Intein Mediated Purification with an Affinity Chitin-binding Tag system. The molecular weight of PTD-MAX determined by the laser flight mass spectrometry was coherent with its theoretical value. The results of the experiment in vivo indicated that the recombinant PTD-MAX can permeate into BBS and inhibitory effects on the food intake were more significantly than maxadilan (P<0.05). The preparation of PTD-MAX lay the foundation for its further application.